DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is a subtype of breast cancer with strong aggressiveness and poor clinical treatment effect, accounting for about 10–20% of breast cancer cases. N(6)-methyldeoxyadenosine (6mA) is the most conservative DNA modification in prokaryotes and eukaryotes. It is widely...

Full description

Bibliographic Details
Main Authors: Xianneng Sheng, Jinqiu Wang, Yu Guo, Jiabo Zhang, Jin Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.616098/full
_version_ 1818573168930979840
author Xianneng Sheng
Jinqiu Wang
Yu Guo
Jiabo Zhang
Jin Luo
author_facet Xianneng Sheng
Jinqiu Wang
Yu Guo
Jiabo Zhang
Jin Luo
author_sort Xianneng Sheng
collection DOAJ
description Triple negative breast cancer (TNBC) is a subtype of breast cancer with strong aggressiveness and poor clinical treatment effect, accounting for about 10–20% of breast cancer cases. N(6)-methyldeoxyadenosine (6mA) is the most conservative DNA modification in prokaryotes and eukaryotes. It is widely found in bacteria and has such functions as DNA mismatch repair, chromosome separation and virulence regulation. We determined that 6mA was modified in TNBC cell line MDA-MB-231 and the TNBC tissue. Meanwhile, compared with normal tissues, the expression level of 6mA and its methylase N6AMT1 was significantly decreased in TNBC tissue. MDA-MB-231cells were cultured with 8μM Olaparib for 2 months to construct drug-resistant cell line 231-RO. It was found that the level of 6mA also increased significantly, and the expression of N6AMT1 or ALKBH1 could effectively influence the drug resistance. Subsequently, we found that LINP1 was highly expressed in 231-RO, which was involved in DNA repair, and the expression of LINP1 could be positively regulated by 6mA modification. LINP1 expression level is directly related to TNBC drug resistance. The above results indicate that 6mA may be a new biological marker of TNBC. Meanwhile, 6mA modification may be involved in the regulation of Olaparib resistance.
first_indexed 2024-12-15T00:07:28Z
format Article
id doaj.art-765197f1847242a59d77809f5377329f
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-15T00:07:28Z
publishDate 2021-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-765197f1847242a59d77809f5377329f2022-12-21T22:42:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-02-011010.3389/fonc.2020.616098616098DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast CancerXianneng ShengJinqiu WangYu GuoJiabo ZhangJin LuoTriple negative breast cancer (TNBC) is a subtype of breast cancer with strong aggressiveness and poor clinical treatment effect, accounting for about 10–20% of breast cancer cases. N(6)-methyldeoxyadenosine (6mA) is the most conservative DNA modification in prokaryotes and eukaryotes. It is widely found in bacteria and has such functions as DNA mismatch repair, chromosome separation and virulence regulation. We determined that 6mA was modified in TNBC cell line MDA-MB-231 and the TNBC tissue. Meanwhile, compared with normal tissues, the expression level of 6mA and its methylase N6AMT1 was significantly decreased in TNBC tissue. MDA-MB-231cells were cultured with 8μM Olaparib for 2 months to construct drug-resistant cell line 231-RO. It was found that the level of 6mA also increased significantly, and the expression of N6AMT1 or ALKBH1 could effectively influence the drug resistance. Subsequently, we found that LINP1 was highly expressed in 231-RO, which was involved in DNA repair, and the expression of LINP1 could be positively regulated by 6mA modification. LINP1 expression level is directly related to TNBC drug resistance. The above results indicate that 6mA may be a new biological marker of TNBC. Meanwhile, 6mA modification may be involved in the regulation of Olaparib resistance.https://www.frontiersin.org/articles/10.3389/fonc.2020.616098/fulltriple negative breast cancer (TNBC)6mAMDA-MB-231Olaparib resistanceLINP1
spellingShingle Xianneng Sheng
Jinqiu Wang
Yu Guo
Jiabo Zhang
Jin Luo
DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
Frontiers in Oncology
triple negative breast cancer (TNBC)
6mA
MDA-MB-231
Olaparib resistance
LINP1
title DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
title_full DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
title_fullStr DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
title_full_unstemmed DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
title_short DNA N6-Methyladenine (6mA) Modification Regulates Drug Resistance in Triple Negative Breast Cancer
title_sort dna n6 methyladenine 6ma modification regulates drug resistance in triple negative breast cancer
topic triple negative breast cancer (TNBC)
6mA
MDA-MB-231
Olaparib resistance
LINP1
url https://www.frontiersin.org/articles/10.3389/fonc.2020.616098/full
work_keys_str_mv AT xiannengsheng dnan6methyladenine6mamodificationregulatesdrugresistanceintriplenegativebreastcancer
AT jinqiuwang dnan6methyladenine6mamodificationregulatesdrugresistanceintriplenegativebreastcancer
AT yuguo dnan6methyladenine6mamodificationregulatesdrugresistanceintriplenegativebreastcancer
AT jiabozhang dnan6methyladenine6mamodificationregulatesdrugresistanceintriplenegativebreastcancer
AT jinluo dnan6methyladenine6mamodificationregulatesdrugresistanceintriplenegativebreastcancer